Over the last eight years, Eli Lilly relied on a three-decade company veteran to steer it through declining sales and a struggling product pipeline. Now, it’ll rely on another long-time executive for its next chapter.
John Lechleiter has been the company’s CEO since 2008. The announcement Wednesday morning of his retirement comes one day after the firm announced strong revenue and profit for its second quarter, indicating that Lechleiter’s initiatives have paid off.
CEO John Lechleiter said the company's strong R&D pipeline has put it on track to report average annual revenue growth of at least 5 percent through the remainder of the decade.
A hot-selling drug for diabetes sold by Eli Lilly and Co. and a co-partner just got another potential boost, as a government panel narrowly recommended that the companies should be allowed to claim that the drug cuts the risk of cardiovascular death.
After a long swoon, the Lilly Endowment is packing an increasing philanthropic punch. Assets climbed to $11.8 billion in 2015, the fifth straight year they rose.
Indianapolis-based Simon Property Group Inc. and Warsaw’s Zimmer Biomet Holdings vaulted back among the top 500 this year, while local oil refiner Calumet Specialty Products Partners plummeted.
The competition heated up in the $71.5 billion global diabetes market last year after Indianapolis-based Eli Lilly’s and Boehringer Ingelheim’s Jardiance unexpectedly reduced the risk of heart attacks, strokes and deaths in a study.
The Indianapolis-based drugmaker said Tuesday it has built a robust pipeline of drugs that “has the potential” to launch 20 new products in the 10 years between 2014 and 2023.
A federal judge made the award to Lilly’s former executive director of human resources, who quit for health reasons and was later dropped from the company’s extended disability plan.
Lilly got a boost from a stable of new drugs but saw sales tumble for longtime stalwarts Cymbalta and Humalog. Meanwhile, R&D costs rose as the company ushered products through its late-stage pipeline.
Bristol-Myers Squibb Co.’s blockbuster cancer drug Opdivo prolonged survival in cases of recurrent head and neck cancer, a first for patients with the harshest form of the disease who often face a bleak prognosis.
The three drugmakers that dominate the world diabetes market—Eli Lilly and Co., Novo Nordisk A/S and Sanofi—are introducing improved forms of insulin, with a price tag to match.
The Senate easily passed a bill Monday allowing corporations to make a federal case of the theft of trade secrets, but a broader patent-law overhaul backed by businesses including Eli Lilly and Co. faces a rougher road.
Within six months, Eli Lilly and Co. could know whether the Food and Drug Administration has approved its latest drug, baricitinib, a once-a-day tablet for treating rheumatoid arthritis.
For Eli Lilly and Co., the approval rewards a decade-long effort to re-enter the biotech and autoimmune spaces that it helped pioneer in the 1980s but then abandoned in the 1990s.
Shares in Eli Lilly and Co. fell Tuesday on concerns surrounding the potential approval of a drug designed to treat dementia caused by Alzheimer's disease.
The Indiana Biosciences Research Institute, set up just three years ago, announced Wednesday morning that it has been awarded grants of $80 million from the Lilly Endowment and $20 million from the Eli Lilly and Co. Foundation.
The erectile-dysfunction drug, made famous by a slew of quirky commercials, is facing performance issues of its own.
Teva’s acquisition will make it the world’s largest maker of generic medicines, giving it greater negotiating power with governments and private-health insurers.
Strong sales of drugs for diabetes, cancer and animals helped the Indianapolis drugmaker overcome falling sales of older drugs for depression and osteoporosis, pushing up fourth-quarter sales and profit.
